BioTime, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2009 and provided an update on recent corporate developments. Continue Reading

Feintuch Communications, Inc. (www.feintuchcommunications.com) has created an integrated public and investor relations healthcare and life sciences practice, naming Jules Abraham as vice president of the firm and managing director of the new group. Continue Reading

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott’s early- and mid-stage pharmaceutical pipeline. Continue Reading

InterMune, Inc. announced today that the U.S. Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. Continue Reading

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels. Continue Reading

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC. Continue Reading

LinkMed’s portfolio company Likvor has received its first order for the Likvor CELDA™ system from a customer outside Sweden. The order comes from Aalborg Hospital which is the largest hospital in the North Denmark Region. Continue Reading

Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related. Continue Reading

Senesco Technologies, Inc. reported today that the insiders of the Company who had previously purchased all of the convertible debentures, warrants and common stock of Senesco which were formerly held by Stanford Venture Capital Holdings, Inc. have elected, subject to shareholder approval, to convert the convertible debentures at a conversion price of $0.83. Continue Reading

Research and Markets has announced the addition of Frost Sullivan’s new report “Economic Analysis for the Russian Healthcare Industry” to their offering. Continue Reading